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ABSTRACT
Achalasia was a condition marked by peristaltic movement absent in lower esophageal sphincter and segment 
that hypertonic result in imperfect relaxation during food ingestion. Achalasia incidence did not differ between 
men and women, account for 1 in 100,000 people every year with prevalence of 10 in 100,000 people, unrelated 
VSHFL¿FDOO\ZLWKHWKQLFDQGKDVLWVKLJKHVWLQFLGHQFHRQDJHJURXS
Based on its etiology, it was divided into primary and secondary Achalasia, while based on its motility, it was 
into hypermotil, hypomotil, and amotil achalasia. Until present, several therapeutic modalities were available 
to treat Achalasia, among them was pharmacology therapy, botulinum toxin injection via endoscopy, pneumatic 
dilatation, Heller myotomy surgery, and per oral endoscopy myotomy (POEM).
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ABSTRAK
Akalasia merupakan suatu keadaan yang ditandai dengan tidak adanya peristaltik di esofagus bagian bawah 
dengan spingter esofagus bagian bawah (LES) yang hipertonik sehingga tidak terjadi relaksasi sempurna saat 
menelan makanan. Angka kejadian akalasia pada perempuan dan laki laki adalah sama, yaitu 1 dari 100.000 
orang per tahun dengan prevalensi 10 pada 100.000 orang, tidak didapatkan pada ras khusus dan angka kejadian 
tertinggi pada usia 30-60 tahun. 
Berdasarkan etiologi terdapat dua jenis akalasia, yaitu primer dan sekunder sedangkan berdasarkan motilitas 
terdapat tiga jenis akalasia, yaitu akalasia hipermotil, akalasia hipomotil, dan akalasia amotil. Hingga saat ini, 
terdapat beberapa modalitas terapi akalasia, antara lain intervensi farmakologi, injeksi toksin botulinum per 




in 1674 after he use whale bone to dilate his patients 
esophagus because of lower esophageal sphincter 
relaxation failure. Achalasia was progressive idiopathic 
neural degeneration of Auerbach myenteric plexus, 
result in food static during ingestion and esophagus 
dilatation. This condition will lead to several symptoms 
and complication, depend on its severity and duration.1,2 
Some Literatures said that Achalasia was a primary 
GLVRUGHU RI HVRSKDJXVZLWK UHOD[DWLRQ LQVXI¿FLHQF\
of lower esophageal sphincter as its etiology, with 
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UDGLRJUDSKLF¿QGLQJVRI DSHULVWDOWLF HVRSKDJXVZLWK
minimal openings, called bird-beak sign.3
Incidence of Achalasia in men and women was 
similar, account for 1 from 100,000 people every 
year with prevalence of 10 in 100,000 people, did 
QRWVSHFL¿FIRUVRPHHWKQLFVDQGKLJKHVW LQFLGHQFH
was found in 30-60 age groups. In US, 2000 cases of 
Achalasia was reported every year, mostly at 25-60 
age groups, and rarely found in children. Otherwise, 
in Gastroentero-hepatology division, Internal Medicine 
Department, Faculty of Medicine, University of 
Indonesia/Dr. Cipto Mangunkusumo Hospital, 48 
cases was found during 5 years period (1984-1988), 
mostly with the same age groups.2,3Achalasia was 
not a rare condition. This could be seen in middle-
aged population, clinically marked with dysphagia, 
regurgitation, and epigastric discomfort. Clinically, 
Achalasia was divided into primary and secondary, 
based on its etiology.2,3
American collage Gastroenterology Clinical 
Guideline in Diagnosis and Management of Achalasia 
in 2013 recommended barium esophagogram 
to assess esophageal emptying, esophagogastric 
junction morphology both during gastric emptying 
and to evaluate its motility. Endoscopy procedure 
to see gastroesophageal junction and gastric cardia 
was recommended in all patients with Achalasia 
to eliminate the possibility of pseudoachalasia.3If 
irreveribe functiona disorder happened, the main 
therapy for Achalasia was palliative treatment. 
Dominant symptoms of this disorder was progressive 
dysphagia, regurgitation, chest pain, and weight loss.3
ETIOLOGY
Achalasia was divided into primary  and secondary 
Achalasia. In primary Achalasia, the exact etiology is 
unknown, probably caused by neutropic virus infection 
result in dorsal vagal nucleus lesion in brainstem and 
mesenteric ganglia in esophagus. Hereditary factor 
also has a role in this disorder. Otherwise, secondary 
Achalasia was caused by infection, intraluminar tumor 
such as cardia tumor, extraluminal pressure from 
pancreatic pseudocyst, anticholinergic drugs, or post 
vagotomi operation.2
PATHOPHYSIOLOGY
Esophagus main function is to deliver food ingested 
from faring to stomach by peristaltic movement 
ranged from 5-15 seconds. In upper and lower part 
of esophagus, a sphincter was important for gastric 
DFLGUHÀX[EDUULHUWRHVRSKDJXVDQGQRUPDO\LQWRQLF
or constriction state, except during food ingestion. 
Esophagus mucosa was base and not suitable for acid 
from gastric secretion. Submucosal layer has secretory 
cells which produce mucus in order to help food 
movement during ingestion process.4
At normal state, esophagus shown two types 
of peristaltic: primary peristaltic and secondary 
peristaltic. Primary peristaltic was only a movement 
following previous peristaltic movement in faring and 
continuing to esophagus during ingestion process. 
This movement period start from faring to stomach 
was estimated for 8 to 10 seconds. But, food ingestion 
durin erect position result in faster food movement, 
about 5-8 seconds, because of gravity effect. If primary 
peristaltic movement fail to push all the food into 
stomach, secondary peristaltic movement than started. 
This movement start from mienteric nerve and several 
UHÀH[HVIURPDIIHUHQWYDJDOQHUYHIURPHVRSKDJXVWR
medulla than back to esophagus.4
In the lower part of esophagus, about towo to 
¿YH FHQWLPHWHU DERYH VWRPDFK HVRSKDJHDO FLUFXODU
muscle functioned as gastroesophageal sphincter. 
Anatomically, this sphincter was not differ to other 
esophagus parts. Physiologically, sphincter will have 
tonic constriction (with intraluminal pressure of 30 
mmHg), differ from middle esophagus which in normal 
condition was in relaxation state. When peristaltic 
movement during ingestion process pass esophagus, 
receptive relaxation process will relax lower esophageal 
sphincter before peristaltic movement and allow food 
to enter stomach. Rarely, sphincter does not relax, so 
that the condition called Achalasia happened.4
CLINICAL MANIFESTATION
Dysphagia of both solid and liquid food was the 
most common symptoms of achalasia, followed by 
regurgitation, chest pain, nausea, vomiting, weight 
loss, and night cough. Otherwise, chest pain was the 
PDLQ V\PSWRPV RI JDVWURHVRSKDJHDO UHÀX[ GLVHDVH
(GERD) caused by esophagus irritation from gastric 
acid. In patients with Achalasia, this symptoms could 
be caused by gastric acid retention or toxin produced 
by fermented lactate by bacteria in esophagus.3
Achalasia was divided into three types (Figure 
1) based on its motility. First type is hypermotile 
Achalasia, a vigorous Achaalasia, with pain dysphagia 
and regurgitation symptoms. Second type is hypomotile 
Achalasia with dysphagia, pain, and regurgitation as its 
symptoms. The last type was amotile Achalasia with 
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dysphagia and regurgitation symptoms. In amotile 
Achalasia, there were failure of normal peristaltic 
so that esophagus was widely dilated in chronic 
Achalasia.5,6
There were several diagnostic modalities to evaluate 
calcium channel blocker and long acting nitrate was 
effective to lower pressure in LES and sometimes 
reduce dysphagia, but did not improve its relaxation 
ability or peristaltic movement of LES.7
Because of longer transit time and delayed in 
esophagus emptying, which was a characteristic of 
Achalasia, absorption and effectivity of any oral 
drugs cannot be calculated. Those drugs was better 
used via sublingual route, such as nifedipine 10-30 
mg sublingual for 30-45 minutes before meals and 
ISDN 5 mg sublingual 10-15 minutes before meals. 
Those drugs reduce pressure in LES for about 50%. 
Ong acting nitrate has a shorter time of action, 3-27 
minutes, and showd a better clinical improvement in 
53-87% case compared to nifedipine that works for 
30-120 minutes with 0-75% effectivity.7
The main limit in those drugs is its short duration of 
action that only reduce some symptoms and reduce its 
HI¿FDF\LQORQJWHUPXVH%HVLGHVLWVVLGHHIIHFWOLNH
peripheral edema, headache, and hypotension could 
be found in 30% patients.7
Drugs were used limited to patient in early 
condition without esophageal dilatation, or in patients 
ZDLWLQJIRUGH¿QLWLYHWUHDWPHQWRUSDWLHQWLQKLJKULVN
that refuse to undergo invasive procedures. Drugs were 
also indicated in severe Achalasia with chest pain 
symptoms. Pharmacotherapy in this condition was 
highly recommended.7
Endoscopic Botolium Toxin Injection 
Toxin botulinum is a neuro toxin works to inhibit 
neurotransmitter in terminal cholinergic receptor. 
Botulinum toxin-A that used for Achalasia therapy 
works by breaks SNAP-25 protein molecule in 
presynaptic membrane, so that acethylcholine relese 
Figure 1. Types of Achalasia5
Achalasia, such as manometry, barium esophagogram, 
esophagoduodenoscopy, and esophagus CT-scan.6
TREATMENT
Since 17th century, achalasia therapy was started. 
6XUJHRQVKDYHPDGHVLJQL¿FDQWLPSURYHPHQWLQ$FKDODVLD
therapy.1 Otherwise, until now, none of achalasia therapy 
could change its pathology and all treatment was just a 
palliative of its clinical manifestation3
Pharmacology
Based on Society of American Gastrointestinal and 
Endoscopic Surgeons in Guidelines for the Surgical 
Treatment of Esophageal Akalasiain 2009,the goal of 
pharmacotherapy was to help obstruction reduction 
and improve lower esophageal sphincter relaxation 
function. Several pharmacological agents such as 
Figure 2. Botulinum toxin mechanism of action and injection location9,10
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was blocked and inhibit acetylcholine exocytosis to 
synaptic area. This will result in transient muscle 
weakness by blocking cholinergic stimulation in LES 
(Figure 2).1
Botulinum toxin injection locally could reduce LES 
pressure and increase esophagus passive emptying. 
Toxin injected via sclerotherapy during endoscopy. 
In normal condition, 80 to 100 unit of Botulinum 
toxin-A was injected in each LES quadrant to reduce 
its pressure, increase esophageal opening, and improve 
esophageal emptying.1,8
Clinical effect from single injection was short 
term effect with relaps incidence more than 50% in 6 
months. Otherwise, repeated injection could give more 
effect in 70-90% patients. A report showed that 21% of 
newly diagnosed Achalasia patients was treated using 
botulinum toxin as early modalities with injection 
duration of 6 months. Good response from botulinum 
toxin injection was found in patients aged less than 50 
years old and patients with severe Achalasia.1,8
This therapy was safe, only 10% complained chest 
SDLQDIWHULQMHFWLRQEXWPRVWO\GLGQRWUHTXLUHVSHFL¿F
therapy. But, repreated injeaction could make myotomy 
procedure during surgery seems harder because of 
adhesion of muscular layer and increase perforation 
possibility in mucosa. Regarding to patient safety, 
botulinum toxin injeaction could be given if no other 
choice present or if surgery correction contraindicated, 
and in patients with survival rate of 2 years.1
Pneumonic Dilatation
Dilatation procedure was firstly done to treat 
achalasia. This principle of therapy is to weakend 
/(6E\WHDULQJLWVPXVFOH¿EHUUDGLDOO\IURPLQVLGH
esophagus. Endoscopic dilatation was believed as the 
most safe no surgical therapy for achalasia. Pneumatic 
dilator were preffered than stiff dilator in achalasia 
therapy because of its effect that widening and break 
muscle fibre in LES. Several pneumatic dilator 
DYDLODEOHWRGD\KDYHWKHVDPHHI¿FDF\DQGVDIHW\EXW
only few data could support it.1
Dilatation treatment was slowly reduce its 
symptoms. The most simple treatment to done is Hurst 
plugging procedure, made from mercury-contained 
rubber, have four different size in F (French) scale. 
It works principally based on gravitation using the 
smallest radius plug to the biggest. Its effectivity only 
50% with no relaps case, 35% with relaps, and 15% 
failure to respond.2
The most recommended procedure was LES 
dilatation using pneumatic dilator. This procedure 
was used in recent 30 years with the most succesfull 
rate of 75-85% after repeated dilatation. Complication 
VXFKDVHVRSKDJHDO UHÀX[RUHVRSKDJHDOSHUIRUDWLRQ
were rarely found. This special technique was not only 
based on it size, but also based on its duration of LES 
dilatation, range from seconds to 5 minutes. Balloon 
Figure 3. Pneumatic dilatation9
was dilated perfectly in short time to get optimum 
LES dilatation. In 60 seconds, balon was reexpanded 
in several minutes, and in each procedure was using 
maximum two ballon (Figure 3).2
The use of dilator made from polyethylene has a 
succesfull rate of 93% with lower complication during 
4 years follow up. Fluoroscopy guided endoscopy was 
effective to dilate balloon. Pneumatic dilatation was 
done using endoscopy in sedated patients, result in 60% 
reduce in LES pressure and 79% symptos resolution. A 
report from Cleaveland showed that 41% of new cases 
was treated with pneumatic therapy, result in clinical 
response of 86% and 54% esophagus emptying. 1,11
Pneumatic Dilatation vs. Botulinum Toxin Injection
In randomized study involving 42 patiens, 
botulinum injection and pneumatic dilatation was 
happened in 70% and 32%, respectively, in 12 months. 
A Cochrane database review in sic studies involving 
178 patients showed statistically indifferent after 
four weeks of intervention. Three research, including 
reviewer, showed a remisiion of about 33 cc per 47cc 
after pneumatic injection. This also happened in 11 
of 43 patients after both botulinum injection and 
pneumatic dilatation. Relative risk was 2,67. This 
showed that pneumatic dilatation was more effective 
than botulinum injection in long term Achalasia3
Laparoscopic Heller Myotomy (LHM)
Surgical therapy in Achalasia was known as Heller 
myotomy, a procedure where muscle surrounding 
esophagus was exposed and cut. Conventional surgery 
was using long incision in thorax. Recent years, 
laparoscopic approach have been use as minimal 
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invasive concept similar to open-surgery concept. This 
PHWKRGZDVKDYLQJORWRIEHQH¿WEHFDXVHRILWVVKRUWHU
length of stay in hostpital, less pain, smaller operation 
scar, and faster recovery time. Laparoscopic approach 
was safe and effective in achalasia therapy, although 
VRPHWLPHVDQDWRPLFDOYDULDWLRQPDGHLWVOLJKWGLI¿FXOW10
A meta-analysis that compare short term and 
long term effect of LHM and balloon dilatation via 
endoscopic was done. From 16 studies consist of 590 
LHM procedure and balloon dilatation via endoscopy 
with follw up in 12, 24, and 60 months, it can be 
concluded an OR of 2,2 in 12 months, 5,06 in 24 
months, and 29,83 in 60 months of LHM superiority 
as the main choice of therapy. Besides, only 18 patients 
reported having redilatation after LHM procedure, 
while 110 patients in balloon dilatation, even 36 among 
them should undergo myotomy as its retreatmen.12
LHM was found to be effective with long term 
outcome. Most of its risk came from general anesthesia 
procedure. Esopohageal perforation is one of the 
complication, but could be detected during operation 
and repaired without serious further complication.9
Peroral Endoscopy Myotomy (POEM)
POEM is a technique involving tunneling between 
esophageal muscle to treat achalasia, especially 
with Chagas disease. This procedure was done via 
endoscopy so that no exterior incision was made. 
POEM was effective to cure dysphagia symptom in 
Achalasia. After this procedures, achalasia was have 
Eckaradt score 0 or 1. In a study using barium intake 
showed a complete emptying in 90% and found to have 
lower esophageal pressure. Sphincter pressure were 
reduced after this procedure, but not as dramatically 
as patients undergo LHM procedure. This procedure 
was done via endoscopy in general anesthesia. A 
tunnel was made below esophageal deeper layer until 
UHDFK/(6(VRSKDJHDOPXVFOH¿EHUDQGJDVWULFFDUGLD
then resected during endoscopy. Early result of this 
procedure was promising. But, esophageal damage risk 
still possible and there were no long term experience 
result of this therapy. GERD risk after procedure 
which needed a lifetime antacid was happened in 32% 
patients. POEM does not cure Achalasia, but this was 
a palliative procedure.13
POEM was fortly done in September 2008 in 
our institution. POEM with the longest follow up, 2 
\HDUVZDV¿UVWO\UHSRUWHGLQ2FWREHU$OORYHU
the world, there have been 900 case that successfully 
treated with POEM. One of its contraindication was 
general anesthesia intolerance.13
Figure 4. POEM procedure13
CONCLUSION
There were several types of Achalasia based on 
its etiology and motility. Modality choices to treat 
Achalasia was more various in recent years. But, there 
were no therapy yet to change its pathology, so that 
those therapies were just palliative therapies.
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